Papers on Parkinson's disease risk

Who was studied890,712 patients with hypertension, against users of non-RAAS blood-pressure drugs

What changedParkinson's disease risk was lower with irbesartan (HR = 0.588) and olmesartan (HR = 0.797) than with non-RAAS blood-pressure drugs

The catchSmoking, socioeconomic position, and education could confound the association; none were adjusted for

Who was studied819,575 women, 18 years, against women without prior vascular disease

What changedParkinson's disease risk was higher in women with prior ischemic heart disease (hazard ratio 1.45) and cerebrovascular disease (1.51)

The catchVascular disease can be an early manifestation of Parkinson's disease before motor symptoms appear

Who was studied19,859 patients with newly diagnosed OMCN, against age- and sex-matched controls

What changedParkinson's disease risk was higher in patients with ocular motor cranial neuropathy than matched controls (hazard ratio 1.550)

The catchEarly undiagnosed Parkinson's disease may have preceded the eye nerve diagnosis

Who was studiedPeople with Parkinson's disease and PD-free controls

What changedParkinson's disease risk and age at onset showed no clear association with genetic variation in diabetes drug targets

The catchDPP-4 genetic proxies failed the diabetes-risk validation check, weakening results for this drug class

Who was studied23,475 participants aged ≥60 years

What changedCumulative alcohol-attributable risk by age 90 was 32.1% for initiation at age 20 against 4.9% for age 40

The catchAlcohol cessation was not modeled as a separate transition, risking sick-quitter bias